Labcorp has acquired MLM Medical Labs, expanding its worldwide central laboratory and biomarker capabilities for clinical studies.

MLM is a central and speciality laboratory provider operating in Germany, South Africa and the US.

This move combines Labcorp’s existing global infrastructure with MLM’s established network and scientific service model.

The companies have not disclosed the financial details of the transaction.

With the addition of MLM, Labcorp operates a wholly owned laboratory network across Africa, Asia, Europe and North America.

This expansion will support clinical trial sponsors with more consistent scientific and operational oversight in multinational studies.

Labcorp executive vice president and biopharma laboratory services president Brian Caveney said: “Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programmes.

“MLM complements Labcorp’s existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies.

“Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide.”

The acquisition brings together Labcorp’s scientific capabilities and operational scale with MLM’s infrastructure.

It also enhances Labcorp's presence in key clinical research markets, such as Africa, where MLM runs a fully College of American Pathologists-accredited central laboratory.

Evercore acted as Labcorp’s exclusive financial adviser. Legal counsel was provided by Pierson Ferdinand and Hogan Lovells.

In July, Labcorp launched Marker by Labcorp Genetic Health Panel, a test aimed at expanding consumer access to information about hereditary risks for more than 100 medically actionable conditions.

The test is available through Labcorp OnDemand and analyses 163 genes linked to hereditary cancer, cardiovascular diseases and metabolic disorders.